Gloria Vaghi (Italy)
IRCCS Mondino Foundation- University of Pavia Headache Science & Neurorehabilitation Center- Department of Brain and Behavioral SciencesAuthor Of 1 Presentation
ONE-YEAR TREATMENT WITH ERENUMAB: HOW DOES IT AFFECT CHRONIC MIGRAINE IN DIFFICULT-TO-TREAT PATIENTS?
- Gloria Vaghi (Italy)
Abstract
Background and Aims:
Evaluating the efficacy of one-year treatment with erenumab in a cohort of patients with chronic migraine, with and without medication overuse headache, who previously failed at least 3 preventive therapies.
Methods:
We analyzed 82 patients (F59, M23, mean age:49.5+9.8, chronic migraine history: 12.9+10.7yrs). The most represented comorbidities (59%) were psychiatric conditions (e.g. depression and anxiety). Erenumab (70-140mg) was administered monthly for 13 treatments (T1 through T13). Our primary outcome measure was the pattern reversal of migraine from chronic to episodic. Thirteen patients(16%) interrupted treatment, 11 subjects for poor efficacy, after a mean of 7.3 months. We collected clinical data on headache features (diaries), disability (MIDAS, HIT-6), allodynia, anxiety and depression scales (questionnaires) at baseline and quarterly.
Results:
Patients with a pattern reversal from chronic to episodic migraine (i.e.>50%responders) were 33.3% at T1, rising to 71% at T13(Fig.1). Super-responders (i.e.>75%responders) were 9.7% at T1 reaching 34.3% at T13. A significant improvement in migraine days and symptomatic intake was detected already at T1 and persisted over the one-year treatment(Fig.2). An improvement in MIDAS and HIT-6 scores was detected from T3(p<0.001), while allodynia intensity decreased significantly from T6(p<0.001)(Fig.3) and anxiety and depression scores after T9 (HADS-A p=0.03,HADS-D p=0.01). Mild side effects were reported by 50% of patients (predominantly constipation, cutaneous reactions and fatigue).
Conclusions:
Erenumab induced a high percentage of pattern reversal in difficult-to-treat patients with chronic migraine. Reduction of monthly migraine days was already significant after the 1st month of treatment, other clinical parameters improved significantly over time. Erenumab benefit persisted for the entire treatment period.
Presenter of 1 Presentation
ONE-YEAR TREATMENT WITH ERENUMAB: HOW DOES IT AFFECT CHRONIC MIGRAINE IN DIFFICULT-TO-TREAT PATIENTS?
- Gloria Vaghi (Italy)
Abstract
Background and Aims:
Evaluating the efficacy of one-year treatment with erenumab in a cohort of patients with chronic migraine, with and without medication overuse headache, who previously failed at least 3 preventive therapies.
Methods:
We analyzed 82 patients (F59, M23, mean age:49.5+9.8, chronic migraine history: 12.9+10.7yrs). The most represented comorbidities (59%) were psychiatric conditions (e.g. depression and anxiety). Erenumab (70-140mg) was administered monthly for 13 treatments (T1 through T13). Our primary outcome measure was the pattern reversal of migraine from chronic to episodic. Thirteen patients(16%) interrupted treatment, 11 subjects for poor efficacy, after a mean of 7.3 months. We collected clinical data on headache features (diaries), disability (MIDAS, HIT-6), allodynia, anxiety and depression scales (questionnaires) at baseline and quarterly.
Results:
Patients with a pattern reversal from chronic to episodic migraine (i.e.>50%responders) were 33.3% at T1, rising to 71% at T13(Fig.1). Super-responders (i.e.>75%responders) were 9.7% at T1 reaching 34.3% at T13. A significant improvement in migraine days and symptomatic intake was detected already at T1 and persisted over the one-year treatment(Fig.2). An improvement in MIDAS and HIT-6 scores was detected from T3(p<0.001), while allodynia intensity decreased significantly from T6(p<0.001)(Fig.3) and anxiety and depression scores after T9 (HADS-A p=0.03,HADS-D p=0.01). Mild side effects were reported by 50% of patients (predominantly constipation, cutaneous reactions and fatigue).
Conclusions:
Erenumab induced a high percentage of pattern reversal in difficult-to-treat patients with chronic migraine. Reduction of monthly migraine days was already significant after the 1st month of treatment, other clinical parameters improved significantly over time. Erenumab benefit persisted for the entire treatment period.